India's Sun Pharma new cholesterol drug deal to boost revenue, say brokerages
BUZZ-India's Sun Pharma new cholesterol drug deal to boost revenue, say brokerages ** Axis Capital ("add",PT: 2,100 rupees) estimates Sun Pharma's SUN.NS newly licensed cholesterol drug could generate more than $700 million in peak sales
** SUN signed an exclusive deal with LIB Therapeutics to manufacture and commercialise lerodalcibep worldwide, excluding the US and China; financial terms were not disclosed
** Axis says deal marks SUN's entry into fast-growing cholesterol-drug market and could benefit from co's expanded international reach following its acquisition of US-based Organon
** DAM Capital ("buy",PT: 2,269 rupees) says SUN could leverage Organon's established cardiovascular business outside the US to accelerate lerodalcibep's rollout
** SUN up as much as 1.32% at 1,862.30 rupees
** Rated "buy" on avg by 31 analysts, median PT at 2,150 rupees - LSEG-compiled data
** YTD stock up 7.75%
(Reporting by Surbhi Misra in Bengaluru)
((Surbhi.Misra@thomsonreuters.com | X: https://twitter.com/SurbhiMisra_ |;))
Recent news on Sun Pharmaceutical Industries
See all newsROI-US blue wave reshapes Asia's winners and losers: Manishi Raychaudhuri
Brief: Sun Pharma Clarifies Regarding News Report Relating To Company's Assam Facility
Street View: India's Sun Pharma Organon buy, psoriasis drug are risk factors
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses